Interrelation of inflammatory endothelial markers with the severity of bronchial asthma in children
Sažetak
Background: Monocyte chemoattractant protein-1 (MCP)-1 and vascular intercellular adhesion molecule of endothelin-1 (sVCAM-1) are key regulators of the inflammation sites infiltrated with monocytes.
Methods: The levels of MCP-1 and sVCAM-1 during BA exacerbation on the background of therapy in children with various degrees of BA severity as well as correlation relationships between MCP-1, sVCAM-1 and parameters of external respiration function were determined.
Results: The level of MCP-1 and sVCAM-1 in all groups of the examined patients at the period of exacerbation of the disease was significantly higher than in children of the control group. On the background of therapy the levels of MCP-1 and sVCAM-1were decreased in patients of all groups, regardless of BA severity. Negative correlation relationships between MCP-1 and FEV1, PEF, VC, FVC, FEV1/FVC were revealed before and after the therapy.
Conclusions: The increased levels of the above mentioned biomarkers were preserved on the seventh day of therapy. This testifies to the involvement of these chemokines into the formation and prolongation of the inflammatory process. The revealed negative correlation between MCP-1 and the main parameters of pulmonary function testified to participation of chemoattractant MCP-1 in chronic inflammation of the airways.
Reference
Asher I, Pearce N. Global burden of asthma among children. Int J Tuberc Lung Dis. 2014;18(11):1269-78.
Marandi Y, Farahi N, Hashjin GS. Asthma: beyond corticosteroid treatment. Arch Med Sci. 2013;9(3):521-26.
Singh SR, Sutcliffe A, Kaur D, Gupta S, Desai D, Saunders R et al. CCL2 release by airway smooth muscle is increased in asthma and promotes fibrocyte migration. Allergy. 2014;69:1189–97.
Jenna R, Murdoch, Clare M Lloyd. Chronic inflammation and asthma. Mutation Research. 2010;690(1-2):24–39.
Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872–97.
Olivieri D, Chetta A. Therapeutic perspectives in vascular remodeling.in asthma and chronic obstructive pulmonary disease. Chem Immunol Allergy. 2014;99:216-25.
Jennie Gane, Robert Stockley. Mechanisms of neutrophil transmigration across the vascular endothelium in COPD. Thorax. 2012;67(6):553-61.
Ley.K, Laudanna C, Cybulsky MI et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–89.
Peter J, Barnes J. The cytokine network in asthma and chronic obstructive pulmonary disease. Clin Invest. 2008;118:3546–56.
Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10(1):61-86.
Stephan F. van Eeden, Adam Yeung, Kevin Quinlam, and James C. Hogg. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac. Soc. 2005;2(1):61–67.
Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-714
Yeryomenko G. The role of fractalkine and monocyte chemoattractant protein-1 in the progression of asthma. Georgian Med News. 2018;274:125-30.
René M. Roy, Marcel Wüthrich, Bruce S. Klein. Chitin elicits CCL2 from airway epithelial cells and induces CCR2-dependent innate allergic inflammation in the lung. J Immunol. 2012;189(5):2545–52.
Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med. 1997;156:1377–83.
Barnes PJ. How corticosteroids control inflammation. Quintiles Prize Lecture. Br J Pharmacol. 2005;48:245-54.
Tang RB, Chen SJ, Soong WJ, Chung RL. Circulating adhesion molecules in sera of asthmatic children. Pediatr Pulmonol. 2002;33(4):249-54.
Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers. 2011;16:11–21.
Janson C, Ludviksdottir D, Gunnbjornsdottir M, Bjornsson EH, Hakansson L,Venge P. Circulating adhesion molecules in allergic and non-allergic asthma. Respir Med. 2005 Jan;99(1):45-51.
Gosset P, Tillie-Leblond I, Janin A, Marquette CH, Copin MC, Wallaert B, Tonnel AB. Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients. Int Arch Allergy Immunol. 1995;106:69–77.
Montefort S, Holgate ST, Howarth PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J. 1993;6:1044–54.
Hakansson L, Bjornsson E, Janson C, Schmekel B. Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma. J Allergy Clin Immunol. 1995;96:941–50.
Hakansson L, Heinrich C, Rak S, Venge P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol. 1997;99:551–62.
Venge P. Soluble markers of allergic inflammation. Allergy. 1994;49:1–8.
Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW, at el. The inhibitory effects of topically active glucocorticoids on IL-4, IL- 5, and interferon-gamma production by cultured primary CD4 T cells. J Allergy Clin Immunol. 1997;100:511–19.
Rose CE Jr, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation. 2003;10(3-4):273-88.
Royce, SG.;Tang, M. LK.The Effects of Current Therapies on Airway Remodeling in Asthma and New Possibilities for Treatment and Prevention. Current Molecular Pharmacology. 2009;2:169-81.
Tang ML, Wilson JW, Stewart AG, Royce SG. Airway remodelling in asthma: current understanding and implications for future therapies. Pharmacol Ther. 2006;112(2):474-88.